Numerous alliances and scientific partnerships exist between Roche and academic institutes in Switzerland.
Roche is among the three leading research institutions in Switzerland, with some 3,500 employees in the areas of pharmacological and diagnostics research and development.
Since 2000, Roche has conducted more than 100 clinical studies of medications with well over 2,000 patients in Switzerland.
Roche is one of the world’s largest investors in research and development. In Switzerland alone, last year Roche spent 2.4 billion Swiss francs.
Last year Roche employed some 13,000 employees from over 90 countries in Switzerland. This makes Switzerland one of Roche’s three largest locations in the world, along with the United States and Germany.
In Switzerland Roche has 10 cancer medications, many of which improve patients’ chances of survival.
Since 2010, seven innovative products and indications from Roche have been approved in the accelerated process by Swissmedic.
Roche is one of the five most valuable Swiss companies by market capitalisation on the Swiss stock exchange.
In the past three years, Roche has invested some 1.25 billion francs in Switzerland, of which around 1 billion were invested in Basel and Kaiseraugst and 250 million in Rotkreuz.
Four out of five people with diabetes who use insulin pumps in Switzerland rely on a product from Roche.
Roche is the largest provider of medications for hospitals in its home market.
About one-quarter of Roche’s global research and development spending occurs in Switzerland.
Roche is among the largest private employers in Switzerland and, with over 390 trainees in 14 different professions, one of the country’s largest providers of vocational training.
The descendants of the founder of Roche make up the majority of Roche shareholders. Hardly any other major company in the world has such a stable and strong ownership structure.